Otonomy (OTIC) Names New CSO
- Nasdaq hits record; bank earnings validate Wall St. rally
- Intrawest Resorts (SNOW) Exploring a Possible Sale - Reuters
- Alibaba (BABA) Has No Plans to Acquire Rest of Groupon (GRPN) - Source
- Time (TIME) Said to Soon Begin Discussions with Interested Buyers - Bloomberg
- JPMorgan (JPM) Reports Q4 EPS of $1.71
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Otonomy, Inc. (Nasdaq: OTIC) announced the appointment of Kathie M. Bishop, Ph.D., as chief scientific officer. Dr. Bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience. At Ionis Pharmaceuticals, she led translational research and development of programs in the neurology franchise including SPINRAZAä (nusinersen), a treatment for patients with spinal muscular atrophy that is awaiting regulatory approval.
"Kathie is a great fit to lead our development efforts given her neuroscience background and successful track record managing significant development programs from inception through to registration," said David A. Weber, Ph.D., president and CEO of Otonomy. "Furthermore, her extensive experience with local drug delivery in the nusinersen as well as other programs is highly relevant to our focus in developing locally administered therapeutics for otic disorders."
Dr. Bishop succeeds Carl LeBel, Ph.D., who had previously announced his retirement. She joins Otonomy from Tioga Pharmaceuticals where she served as chief scientific officer since 2015. Previously, she served in product development management roles at Ionis Pharmaceuticals including vice president, clinical development. At Ionis, she led translational research and development of a portfolio of programs in the neurology franchise which included clinical-stage products for the treatment of spinal muscular atrophy, myotonic dystrophy, and amytrophic lateral sclerosis and preclinical programs targeting various disorders including retinal degeneration. Prior to Ionis, she served in research and development leadership roles at Ceregene, a company focused on the development of gene therapy products for the treatment of neurodegenerative disorders and retinal diseases. Before joining Ceregene, she worked as a post-doctoral fellow in the Molecular Neurobiology Lab at the Salk Institute in La Jolla. Dr. Bishop obtained her Ph.D. in Neuroscience from the University of Alberta, a B.A. in Psychology from Simon Fraser University and a B.Sc. in Cell Biology and Genetics from the University of British Columbia.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norwood Financial Corp (NWFL) Names William Davis, Jr. as Chairman of the Board
- US Foods (USFD) Names Dirk Locascio as CFO
- Rocky Brands (RCKY) CFO Resigns; Mike Staude Appointed Interim CFO
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!